Evidence map›Paper›PMID 40787892›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Epigenetic Regulation of DAPK1 and Netrin-1 Drives Diabetic Encephalopathy.

Yang Zhou, Jia-Xin Kou, Kai Zheng, Zi-Xuan Guo, Hong-Wei Fan, Wen-Lian Li, Lu-Lu Chu, Jing-Wen Yin, Li-Jie Liu, Nadezhda Brazhe and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Epigenetic Regulation of DAPK1 and Netrin-1 Drives Diabetic Encephalopathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yang ZhouDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Jia-Xin KouDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.ORCID https://orcid.org/0000-0002-7947-8212
Kai ZhengDepartment of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Zi-Xuan GuoDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Hong-Wei FanDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Wen-Lian LiDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Lu-Lu ChuDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Jing-Wen YinDepartment of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Li-Jie LiuDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Nadezhda BrazheFaculty of Biology, M.V. Lomonosov Moscow State University, Moscow, 119234, Russia.
Zhi-Gao XiangDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Feng HuDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Kai ShuDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Ling-Qiang ZhuDepartment of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.ORCID https://orcid.org/0000-0001-9964-9229
Dan LiuDepartment of Medical Genetics, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.

Funding

Hubei Provincial Natural Science Foundation 2022CFA004Hubei Provincial Natural Science Foundation 2023AFA068National Key R&D Program of China 2022ZD0211800National Natural Science Foundation of China 82030032National Natural Science Foundation of China 82261138555National Natural Science Foundation of China 82325017National Natural Science Foundation of China 82371403National Natural Science Foundation of China 82401423Natural Science Foundation of Hubei Province 2022CFA004Natural Science Foundation of Hubei Province 2023AFA068Science and Technology Innovation Program of Hunan Province 2022RC4044Science and Technology Innovation Program of Hunan Province 2024JJ7442
6 · The paper itself

Abstract

Diabetic encephalopathy (DE) is a severe complication of diabetes characterized by cognitive impairment and synaptic dysfunction, while the underlying mechanisms are not clear. Here, a critical role is identified for death-associated protein kinase 1 (DAPK1) in DE pathogenesis using transgenic and streptozotocin-induced diabetic mouse models. Elevated DAPK1 expression in hippocampal excitatory neurons correlates with cognitive deficits, increases neuronal apoptosis, and disrupts synaptic plasticity. Conditional knockout of DAPK1 in CaMKII-positive neurons significantly mitigates these pathological features, improving cognitive performance and synaptic function. Mechanistically, it is demonstrated that reduced hippocampal microRNA (miR)-216a-5p levels in diabetic mice lead to DAPK1 upregulation. Furthermore, DAPK1 suppresses the expression of the neurotrophic factor Netrin-1 (Ntn1) by phosphorylating hepatocyte nuclear factor 1 homeobox A (HNF1A), a key transcription factor. Silencing Ntn1 in wild-type mice induces DE-like symptoms, while intranasal administration of recombinant Ntn1 restores cognitive function and synaptic integrity in diabetic mice. These findings establish an miR-216a-5p/DAPK1/Ntn1 signaling axis as a critical driver of diabetes-induced cognitive dysfunction and suggest Ntn1 as a promising therapeutic target for DE. Here novel insights into the molecular mechanisms are provided underlying DE, and the therapeutic potential of targeting DAPK1 and Ntn1 is highlighted to alleviate diabetes-associated central nervous system complications.

Indexed as

Brain DiseasesDeath-Associated Protein KinasesDiabetes ComplicationsDiabetes Mellitus, ExperimentalEpigenesis, GeneticNetrin-1AnimalsDisease Models, AnimalHippocampusHypoglycemiaMaleMiceMice, Inbred C57BLMice, TransgenicMicroRNAsDapk1 protein, mouseDeath-Associated Protein KinasesMicroRNAsNetrin-1Ntn1 protein, mouseDAPK1diabetic encephalopathyNetrin‐1

Identifiers

PMID40787892
PMCPMC12499468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.